CLAIMS

1. An immunogenic product comprising at least one cytokine conjugated with a carrier protein, wherein the at least one cytokine is IL-13 or a fragment thereof comprising at least 50 amino acids from IL-13, and wherein the carrier protein is CRM_{197}, and wherein the immunogenic product is obtained by a method comprising steps of:

a) contacting the IL-13 or fragment thereof with N-[γ-maleimidobutyryloxy]-succinimide ester (sGMBS);

b) contacting the CRM_{197} with N-succinimidyl-S-acetylthioacetate (SATA), to generate a CRM_{197}-SATA complex;

c) contacting the sGMBS-IL-13 complex obtained at step (a) with the CRM_{197}-SATA complex obtained at step (b).

2. The immunogenic product according to claim **1**, wherein the immunogenic product further comprises IL-4.

3. A composition comprising at least one immunogenic product according to claim **1** or **2**.

4. The composition according to claim **3**, comprising a mixture of an immunogenic product comprising IL-4 and CRM_{197} with an immunogenic product comprising IL-13 and CRM_{197}.

5. The composition according to claim **3** or **4**, comprising a mixture of an immunogenic product comprising IL-4 and CRM_{197} with an immunogenic product comprising IL-13 and CRM_{197} at a weight ratio ranging from 10:1 to 1:10.

6. The composition according to any one of claims **3** to **5**, further comprising at least one pharmaceutically acceptable excipient and/or at least one adjuvant.

7. The composition according to any one of claims **3** to **6**, being an emulsion.

8. A method for producing an immunogenic product according to claim **1** or **2**, the method comprising steps of:

a) contacting the IL-13 or fragment thereof with N-[γ-maleimidobutyryloxy]-succinimide ester (sGMBS);

b) contacting the CRM_{197} with N-succinimidyl-S-acetylthioacetate (SATA), to generate a CRM_{197}-SATA complex;

c) contacting the sGMBS-IL-13 complex obtained at step (a) with the CRM_{197}-SATA complex obtained at step (b).

9. Use of an immunogenic product according to claim **1** or **2**, or a composition according to any one of claims **3** to **7**, in the manufacture of a medicament for treating an inflammatory disorder, wherein said disorder is associated with aberrant IL-13 expression or activity.

10. The use according to claim **9**, wherein the inflammatory disorder is selected from the group comprising asthma (either allergic or non-allergic), allergic conditions (such as, for example, food allergies, venom allergy, allergy to animals, drug allergy, hyper IgE syndrome, allergic rhinitis, allergic conjunctivitis and allergic enterogastritis), atopic disorders (such as, for example, atopic dermatitis, urticaria (including chronic idiopathic urticaria and chronic spontaneous urticaria), eczema), bullous pemphigoid, respiratory disorders (such as allergic and nonallergic asthma, chronic obstructive pulmonary disease (COPD)), nasal polyposis and other conditions involving airway inflammation (such as, for example, eosinophilia, fibrosis and excess mucus production including cystic fibrosis and pulmonary fibrosis, systemic sclerosis (SSc)); inflammatory and/or autoimmune disorders or conditions, gastrointestinal disorders or conditions (such as, for example, inflammatory bowel diseases (IBD) and eosinophilic esophagitis (EE), and eosinophilic-mediated gastrointestinal disease, ulcerative colitis and Crohn's disease); systemic lupus erythematosus, liver disorders or conditions (such as, for example, cirrhosis, and hepatocellular carcinoma), scleroderma; fibrotic diseases or disorders (such as, for example, fibrosis of the liver (such as, for example, fibrosis caused by a hepatitis B and/or C virus)), scleroderma; solid tumors or cancers such as leukemia (such as, for example, B cell chronic lymphocytic leukaemia), glioblastoma, lymphoma (such as, for example, Hodgkin's lymphoma) and mastocytosis.

11. The use according to claim **9** or **10**, wherein the inflammatory disorder is selected from asthma (e.g., allergic asthma), atopic dermatitis, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, food allergy, nasal polyposis and

eosinophilic esophagitis, preferably wherein said inflammatory disorder is allergy, asthma, or atopic dermatitis.

12. The use according to any one of claims **9** to **11**, wherein the medicament is for administration to induce desensitization toward an allergen.

13. Use of an immunogenic product according to claim **1** or **2**, or a composition according to any one of claims **3** to **7**, in the manufacture of a medicament for inducing desensitization of a subject allergic to a specific antigen, wherein said medicament and said specific antigen are to be administered to the allergic subject.